What is claimed is:

1. A method of inducing spinal anesthesia, comprising:
administering spinally a small but anesthetic producing amount of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue hereof to a patient in need of a spinal anesthetic.

2. The method of claim 1 wherein the administering spinally is by intrathecal administration.

3. The method of claim 2 wherein 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue is administered in conjunction with a pharmaceutically acceptable carrier for 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or its biologically active analogue.

4. The method of claim 2 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.1 mg to 3.0 mg.

5. The method of claim 4 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.5 mg to 2.0 mg.

6. A composition for inducing spinal anesthesia, comprising:
a small but anesthetic producing amount of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic

acid or a pharmaceutically active analogue thereof in combination with a pharmaceutically acceptable carrier.

7. The composition of claim 6 wherein the administering spinally is by intrathecal administration.

8. The composition of claim 7 wherein 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue is administered in conjunction with a pharmaceutically acceptable carrier for -6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or its biologically active analogue.

9. The composition of claim 7 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.1 mg to 3.0 mg.

10. The composition of claim 7 wherein the dose of 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid or a pharmaceutically active analogue administered is from 0.5 mg to 2.0 mg.